Pneumococcal Conjugate Vaccine

Links shared publicly online about this topic

Pfizer to supply pneumococcal conjugate vaccines for infants and children

news-medical.net — “Pfizer Inc. today announced it has signed a 10-year Provisional Supply Agreement to supply Prevenar 13* (Pneumococcal Polysaccharide Conjugate Vaccine [13-valent, adsorbed]), the company's 13-valent pneumococcal conjugate vaccine, for infants and young children in the world's poorest countries under the terms of the Advance Market Commitment (AMC) pilot project against pneumococcal disease.View full resource at news-medical.net

  • View Related
  • Share

Most Recently Shared on March 24, 2010 at 5:16 pm By:

Meningitis_News News-Medical.Net Health News

Meningitis News: Pfizer to supply pneumococcal conjugate vaccines for infants and children: Pfizer Inc. today anno... http://bit.ly/coSs8Q

2 years ago...

Prevnar 13, the New 13-Valent Pneumococcal Conjugate Vaccine (December)

theannals.com — “Prevnar 13, the New 13-Valent Pneumococcal Conjugate Vaccine (December)View full resource at theannals.com

  • View Related
  • Share

Most Recently Shared on November 2, 2011 at 3:45 am By:

theannals The Annals Medical Journal

Prevnar 13, the New 13-Valent Pneumococcal Conjugate Vaccine (December): OBJECTIVE:To review the immunogenicity,... http://t.co/UCOTnIgs

7 months ago...

Pneumococcal conjugate vaccine appears to reduce pneumonia, serious complications in infants: Research

news-medical.net — “A pneumococcal conjugate vaccine introduced in the U.S. 10 years ago appears to reduce pneumonia and serious associated complications, such as blood infections, in the vaccine's target range, children less than a year old, according to new research.View full resource at news-medical.net

  • View Related
  • Share

Most Recently Shared on July 19, 2010 at 5:43 am By:

NewsMedical News-Medical.Net Health News

Pneumococcal conjugate vaccine appears to reduce pneumonia, serious complications in infants: Research: A pneumoco... http://bit.ly/ddBw0c

2 years ago...

EC approves Pfizer's pneumococcal conjugate vaccine, Prevenar 13

news-medical.net — “Pfizer Inc. announced today that the European Commission has approved the Company's pneumococcal conjugate vaccine, Prevenar 13 (pneumococcal polysaccharide conjugate vaccine, for active immunization for the prevention of vaccine-type invasive disease caused by Streptococcus pneumoniae in adults aged 50 years and older.View full resource at news-medical.net

  • View Related
  • Share

Most Recently Shared on October 27, 2011 at 12:13 pm By:

Meningitis_News News-Medical.Net Health News

Meningitis News: EC approves Pfizer's pneumococcal conjugate vaccine, Prevenar 13: Pfizer Inc. announced today t... http://t.co/Tf9d5WUY

7 months ago...

Pneumococcal conjugate vaccines effective at preventing child deaths, study suggests

feeds.sciencedaily.com — “A new study concludes that pneumococcal conjugate vaccines (PCV), already known to prevent invasive pneumococcal disease (IPD) and X-ray defined pneumonia, were also effective against child deaths. According to the review, 80 percent of children were less likely to develop vaccine-type IPD, 58 percent all-serotype IPD, and 27 percent x-ray defined pneumonia than children who did not receive the vaccine. Eleven percent of child deaths were also prevented.View full resource at feeds.sciencedaily.com

  • View Related
  • Share

Most Recently Shared on November 18, 2009 at 1:12 am By:

sciencedaily sciencedaily Health News

Pneumococcal Conjugate Vaccines Effective At Preventing Child Deaths, Study Suggests: A new study concludes that pn... http://bit.ly/4AUOBj

3 years ago...

FDA approves Pfizer's Prevnar 13 pneumococcal conjugate vaccine

news-medical.net — “Pfizer Inc. announced today that the United States Food and Drug Administration has granted approval for Prevnar 13" (Pneumococcal 13-valent Conjugate Vaccine [Diphtheria CRM197 Protein]), the Company's 13-valent pneumococcal conjugate vaccine.View full resource at news-medical.net

  • View Related
  • Share

Most Recently Shared on February 25, 2010 at 5:38 am By:

NewsMedical News-Medical.Net Health News

FDA approves Pfizer's Prevnar 13 pneumococcal conjugate vaccine: Pfizer Inc. announced today that the United State... http://bit.ly/bOQF86

2 years ago...

Pneumococcal conjugate vaccination and nasopharyng... [JAMA. 2010] - PubMed result

ncbi.nlm.nih.gov — “PubMed is a service of the U.S. National Library of Medicine that includes over 19 million citations from MEDLINE and other life science journals for biomedical articles back to the 1950s. PubMed includes links to full text articles and other related resources.View full resource at ncbi.nlm.nih.gov

  • View Related
  • Share

Most Recently Shared on September 27, 2010 at 4:05 am By:

MD Consult: News: Panel reviews recommendations for 13-valent pneumococcal conjugate vaccine

mdconsult.com — “MD Consult: News: Panel reviews recommendations for 13-valent pneumococcal conjugate vaccineView full resource at mdconsult.com

  • View Related
  • Share

Most Recently Shared on October 23, 2009 at 10:54 am By:

mdconsult MD Consult Health Site and Medical Publisher

Panel reviews recommendations for 13-valent pneumococcal conjugate vaccine http://bit.ly/3qbXWs

3 years ago...

FDA approves Pfizer's Prevnar 13 pneumococcal conjugate vaccine as a single dose for adults

news-medical.net — “Pfizer Inc. announced today that the U.S. Food and Drug Administration has granted approval of the Company's pneumococcal conjugate vaccine Prevnar 13 (Pneumococcal 13-valent Conjugate Vaccine [Diphtheria CRM197 Protein]) as a single dose for use in adults.View full resource at news-medical.net

  • View Related
  • Share

Most Recently Shared on December 31, 2011 at 9:55 am By:

Meningitis_News News-Medical.Net Health News

Meningitis News: FDA approves Pfizer's Prevnar 13 pneumococcal conjugate vaccine as a single dose for adults: Pf... http://t.co/4eorFS2i

5 months ago...

Sinovac Biotech Submits Clinical Trial Application To SFDA For Pneumococcal Conjugate Vaccine (PCV) - QualityPoint Technologies

qualitypointtech.net — “Sinovac Biotech Ltd. (Nasdaq:SVA - News), a leading provider of biopharmaceutical products in China, announced it submitted the application to commence clinical trials for its 13-valent pneumococcal conjugate vaccine (PCV) to China's State Food and Drug Administration (SFDA) on March 3, 2011. Sinovac initiated its PCV research program in 2008. The vaccine targets infants under two years old. The target population in Chinais estimated at 34 million...View full resource at qualitypointtech.net

  • View Related
  • Share

Most Recently Shared on March 5, 2011 at 2:35 pm By:

MedicalFeed MedicalFeed Health News Feed

Sinovac Biotech Submits Clinical Trial Application To SFDA For Pneumococcal Conjugate Vaccine (PCV): Sinovac Biote... http://bit.ly/eTC5BO

1 year ago...

WHO grants prequalification to Prevenar 13, Pfizer's 13-valent pneumococcal conjugate vaccine for infants & young children - Biotechnology

pharmabiz.com — “The World Health Organization (WHO) has granted prequalification to Prevenar 13 (Pneumococcal polysaccharide conjugate vaccine [13-valent, adsorbed])for active immunization of infants and children from 6 weeksView full resource at pharmabiz.com

  • View Related
  • Share

Most Recently Shared on August 24, 2010 at 11:13 am By:

Lung_Breathing Lungs and Breathing OW Health

WHO grants prequalification to Prevenar 13, Pfizer's 13-valent pneumococcal conjugate vaccine for infants & young ... http://bit.ly/an8GLZ

2 years ago...

Prevention of Pneumococcal Disease Among Infants and Children --- Use of 13-Valent Pneumococcal Conjugate Vaccine and 23-Valent Pneumococcal Polysaccharide Vaccine

cdc.gov — “Prevention of Pneumococcal Disease Among Infants and Children --- Use of 13-Valent Pneumococcal Conjugate Vaccine and 23-Valent Pneumococcal Polysaccharide VaccineView full resource at cdc.gov

  • View Related
  • Share

Most Recently Shared on December 10, 2010 at 2:52 pm By:

HealthTrendster HealthTrendster Health Executive

RECOMMENDATIONS AND REPORTS: Prevention of Pneumococcal Disease Among Infants and Children… http://goo.gl/fb/p6HR3

1 year ago...

Serum and Merck Announce Collaboration to Develop and Expand Global Access to Pneumococcal Conjugate Vaccine - Drugs.com MedNews

drugs.com — “From ENP Newswire (August 8, 2011) ENP Newswire - 08 August 2011 Release date- 05082011 - Serum Institute of India Ltd and Merck (known outside the United StateView full resource at drugs.com

  • View Related
  • Share

Most Recently Shared on August 8, 2011 at 1:08 pm By:

Drugs_Devices Drugs and Devices OW OW Health

Serum and Merck Announce Collaboration to Develop and Expand Global Access to Pneumococcal Conjugate Vacci... http://bit.ly/ofqxY1 #drug

10 months ago...

PLoS Medicine: Monitoring the Introduction of Pneumococcal Conjugate Vaccines into West Africa: Design and Implementation of a Population-Based Surveillance System

plosmedicine.org — “PLoS Medicine is an open-access, peer-reviewed medical journal that publishes outstanding human studies that substantially enhance the understanding of human health and disease.View full resource at plosmedicine.org

  • View Related
  • Share

Most Recently Shared on January 18, 2012 at 11:14 am By:

PLoSMedicine PLoS Medicine Medical Journal

Monitoring the impact of pneumococcal conjugate vaccination in The Gambia: http://t.co/9S42Jt4K

4 months ago...

Merck and Serum Institute Announce Collaboration to Develop and Expand Global Access to Pneumococcal Conjugate Vaccine (PCV) - Drugs.com MedNews

drugs.com — “Aug 3, 2011 - Merck (NYSE MRK), known outside the United States and Canada as MSD, and Serum Institute of India Limited, an Indian company, announced today an aView full resource at drugs.com

  • View Related
  • Share

Most Recently Shared on August 3, 2011 at 2:09 pm By:

Drugs_Devices Drugs and Devices OW OW Health

Merck and Serum Institute Announce Collaboration to Develop and Expand Global Access to Pneumococcal Conju... http://bit.ly/qrFjgU #drug

10 months ago...

The Top 3 resources shared on this topic. More resources.

Key stats and trends about this topic

Related Health Centers

Featuring the top 3 experts for this topic

Advertisement

Share via Email

Share this WisdomCard with others by embedding on your site or blog.

300x260

425x300

560x390